Background: Recent studies have found that women with obstetric disorders are at increased risk for a variety of long-term complications. However, the underlying pathophysiology of these connections remains undetermined. A network-based view incorporating knowledge of other diseases and genetic associations will aid our understanding of the role of genetics in pregnancy-related disease complications. Methods: We built a disease–disease network (DDN) using UK Biobank (UKBB) summary data from a phenome-wide association study (PheWAS) to elaborate multiple disease associations. We also constructed egocentric DDNs, where each network focuses on a pregnancy-related disorder and its neighboring diseases. We then applied graph-based semi-supervised learning (GSSL) to translate the connections in the egocentric DDNs to pathologic knowledge. Results: A total of 26 egocentric DDNs were constructed for each pregnancy-related phenotype in the UKBB. Applying GSSL to each DDN, we obtained complication risk scores for additional phenotypes given the pregnancy-related disease of interest. Predictions were validated using co-occurrences derived from UKBB electronic health records. Our proposed method achieved an increase in average area under the receiver operating characteristic curve (AUC) by a factor of 1.35 from 55.0% to 74.4% compared to the use of the full DDN. Conclusion: Egocentric DDNs hold promise as a clinical tool for the network-based identification of potential disease complications for a variety of phenotypes.
Background: Disease complications, the onset of secondary phenotypes given a primary condition, can exacerbate the long-term severity of outcomes. However, the exact cause of many of these cross-phenotype associations is still unknown. One potential reason is shared genetic etiology—common genetic drivers may lead to the onset of multiple phenotypes. Disease-disease networks (DDNs), where nodes represent diseases and edges represent associations between diseases, can provide an intuitive way of understanding the relationships between phenotypes. Using summary statistics from a phenome-wide association study (PheWAS), we can generate a corresponding DDN where edges represent shared genetic variants between diseases. Such a network can help us analyze genetic associations across the diseasome, the landscape of all human diseases, and identify potential genetic influences for disease complications. Results: To improve the ease of network-based analysis of shared genetic components across phenotypes, we developed the humaN disEase phenoType MAp GEnerator (NETMAGE), a web-based tool that produces interactive DDN visualizations from PheWAS summary statistics. Users can search the map by various attributes and select nodes to view related phenotypes, associated variants, and various network statistics. As a test case, we used NETMAGE to construct a network from UK BioBank (UKBB) PheWAS summary statistic data. Our map correctly displayed previously identified disease comorbidities from the UKBB and identified concentrations of hub diseases in the endocrine/metabolic and circulatory disease categories. By examining the associations between phenotypes in our map, we can identify potential genetic explanations for the relationships between diseases and better understand the underlying architecture of the human diseasome. Our tool thus provides researchers with a means to identify prospective genetic targets for drug design, using network medicine to contribute to the exploration of personalized medicine.
Objective To identify and define a process and framework for biomedical discovery research. Our study aim was to characterize the biomedical discovery lifecycle across data modalities and professional stakeholders involved in biomedical research to address the multiomics data challenges of precision medicine. Materials and Methods We recruited fifteen professionals from various biomedical roles and industries to participate in 60-minute semi-structured interviews, which involved an assessment of common challenges, needs, tasks, and data management methods and a brainstorm exercise to validate each professional’s biomedical research process. We applied a qualitative analysis of individual interviews using a constant comparative approach for emerging themes. Results We found a general process of biomedical discovery across all participants that consisted of four key stages: data plan, data integrity, data analysis, and data-driven discovery. Within each stage of the process, participants highlighted their challenges and needs and emphasized the importance of data integrity and interoperability, particularly during data hand-offs. The process extends across three general levels of data, including non-human, non-clinical human, and clinical human data, to define an overarching framework for biomedical discovery research. Conclusions The proposed framework provides researchers with an opportunity to align workstreams and converge on a single process to conduct biomedical research across stakeholders and data types. Key opportunities were found that can be explored in the health technology space, including generative artificial intelligence, to help tackle multiomics data challenges to advance precision medicine.